ArticleFrontiers in immunology2024
Human milk oligosaccharides differentially support gut barrier integrity and enhance Th1 and Th17 cell effector responses
Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Decoding the HMO‒microbiome axis: bridging maternal milk to infant health outcomes.Gut microbes · 2026Review
- Article
- Human Milk Oligosaccharides: Shaping the Anti-Infective Status in Infancy.Microorganisms · 2026Review
- A Synbiotic of Lacto-Nutrients · 2026Article
- Protective Effects of Human Milk Oligosaccharides (hMOs) on Analgesic, Nonsteroidal Anti-inflammatory Drugs (NSAIDs)-Induced Disruption of Gut Barrier Integrity in Cocultures Mimicking Neuro-Gut Epithelial Cell Crosstalk.Molecular nutrition & food research · 2025Article
- Systemic Availability of Human Milk Oligosaccharides in Infants and Adults: A Narrative Review.Advances in nutrition (Bethesda, Md.) · 2025Review
- Human milk oligosaccharide secretion dynamics during breastfeeding and its antimicrobial role: A systematic review.World journal of clinical pediatrics · 2025Article
- Diet's impact on gut microbial assemblage in health and disease.The Journal of clinical investigation · 2025Review
- Lifelong partners: Gut microbiota-immune cell interactions from infancy to old age.Mucosal immunology · 2025Review
- The Impact of Human Milk Oligosaccharides on Antibiotic-Induced Microbial Dysbiosis and Gut Inflammation in Mice.Antibiotics (Basel, Switzerland) · 2025Article
- Vitamin D enhances the therapeutic effect of TNF-α antibodies through lipid metabolism in overweight IBD patients.Cellular and molecular life sciences : CMLS · 2025Article
- Recent advances in the science of human milk oligosaccharides.BBA advances · 2025Article
- Residents or Tourists: Is the Lactating Mammary Gland Colonized by Residential Microbiota?Microorganisms · 2024Review
- Biological effects of combinations of structurally diverse human milk oligosaccharides.Frontiers in pediatrics · 2024Review
- Human milk oligosaccharides regulate human macrophage polarization and activation in response toFrontiers in immunology · 2024Article
- Interactions of human milk oligosaccharides with the immune system.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human milk oligosaccharides (HMOs) can modulate the intestinal barrier and regulate immune cells to favor the maturation of the infant intestinal tract and immune system, but the precise functions of individual HMOs are unclear. To determine the structure-dependent effects of individual HMOs (representing different structural classes) on the intestinal epithelium as well as innate and adaptive immune cells, we assessed fucosylated (2'FL and 3FL), sialylated (3'SL and 6'SL) and neutral non-fucosylated (LNT and LNT2) HMOs for their ability to support intestinal barrier integrity, to stimulate the secretion of chemokines from intestinal epithelial cells, and to modulate cytokine release from LPS-activated dendritic cells (DCs), M1 macrophages (MØs), and co-cultures with naïve CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.